TY - JOUR
T1 - The Society of Thoracic Surgeons Risk Model for Surgical Aortic Valve Replacement After Transcatheter Aortic Valve Replacement
AU - Hawkins, Robert B
AU - Bonnell, Levi
AU - Mehaffey, J Hunter
AU - Wyler von Ballmoos, Moritz
AU - Kim, Karen M
AU - Kaneko, Tsuyoshi
AU - Nguyen, Tom C
AU - MacGillivray, Thomas
AU - Thourani, Vinod H
AU - Badhwar, Vinay
AU - Fukuhara, Shinichi
AU - Habib, Robert H
AU - Bowdish, Michael E
N1 - Copyright © 2026. Published by Elsevier Inc.
PY - 2026/7/20
Y1 - 2026/7/20
N2 - BACKGROUND: Recent evidence suggests cardiac surgery after transcatheter aortic valve replacement (TAVR) carries additional risk. Herein we describe validation of a risk model for surgical aortic valve replacement (SAVR) after prior TAVR and risk distribution over time.METHODS: Patients undergoing SAVR (7/2014-3/2025) were extracted from the Society of Thoracic Surgeons (STS) Adult Cardiac Surgery Database. Patients were excluded for no prior TAVR, concomitant arch/descending aortic procedures, other major surgery, or missing operative mortality data. Patients undergoing proximal aortic or other valve surgery were included. De novo, parsimonious models were built for all 8 STS outcomes.RESULTS: Among 651,398 SAVR patients during the study period, 5,708 had SAVR after TAVR with 2,298 (40.3%) isolated SAVR-after-TAVR and 3,410 (59.7%) concomitant procedures. The risk model for SAVR-after-TAVR had excellent discrimination for operative mortality (AUC 0.82) and morbidity or mortality (AUC 0.73). Calibration was excellent across risk deciles for all demographic and surgical subgroups. Of isolated SAVR-after-TAVR cases that might qualify for redo-TAVR (excluding endocarditis, root enlargement and emergent cases), 53.3% (753/1,334) had predicted risk of mortality <3%, and the operative mortality rate decreased over time from 13.1% to 3.5%. Given improvement over time, era was included as an interaction term in the model for isolated SAVR cases, leading to stable observed-to-expected ratios.CONCLUSIONS: Mortality rates for SAVR-after-TAVR have decreased. The risk model has excellent performance and demonstrates a large cohort of TAVR explant patients can be classified as low risk. The new risk model allows for accurate risk estimates to inform clinical decision-making.
AB - BACKGROUND: Recent evidence suggests cardiac surgery after transcatheter aortic valve replacement (TAVR) carries additional risk. Herein we describe validation of a risk model for surgical aortic valve replacement (SAVR) after prior TAVR and risk distribution over time.METHODS: Patients undergoing SAVR (7/2014-3/2025) were extracted from the Society of Thoracic Surgeons (STS) Adult Cardiac Surgery Database. Patients were excluded for no prior TAVR, concomitant arch/descending aortic procedures, other major surgery, or missing operative mortality data. Patients undergoing proximal aortic or other valve surgery were included. De novo, parsimonious models were built for all 8 STS outcomes.RESULTS: Among 651,398 SAVR patients during the study period, 5,708 had SAVR after TAVR with 2,298 (40.3%) isolated SAVR-after-TAVR and 3,410 (59.7%) concomitant procedures. The risk model for SAVR-after-TAVR had excellent discrimination for operative mortality (AUC 0.82) and morbidity or mortality (AUC 0.73). Calibration was excellent across risk deciles for all demographic and surgical subgroups. Of isolated SAVR-after-TAVR cases that might qualify for redo-TAVR (excluding endocarditis, root enlargement and emergent cases), 53.3% (753/1,334) had predicted risk of mortality <3%, and the operative mortality rate decreased over time from 13.1% to 3.5%. Given improvement over time, era was included as an interaction term in the model for isolated SAVR cases, leading to stable observed-to-expected ratios.CONCLUSIONS: Mortality rates for SAVR-after-TAVR have decreased. The risk model has excellent performance and demonstrates a large cohort of TAVR explant patients can be classified as low risk. The new risk model allows for accurate risk estimates to inform clinical decision-making.
U2 - 10.1016/j.athoracsur.2026.07.001
DO - 10.1016/j.athoracsur.2026.07.001
M3 - Article
C2 - 42476250
SN - 0003-4975
JO - The Annals of thoracic surgery
JF - The Annals of thoracic surgery
ER -